TEST:

Labcorp® Plasma Detect™

Postoperative ctDNA detection using a tumour-informed WGS test improves prognosis stratification in stage III colon cancer and may help to personalize adjuvant treatment.

Adding TSR to ctDNA and pTN stage improved risk stratification of stage III CC patients receiving ACT. One-third of the patients had none of the biomarkers and could be considered for de-escalation based on their very low RR. In addition to ctDNA-positive patients, ctDNA-negative patients with a pT4/N2 stroma-high tumor may require treatment escalation to reduce their high RR.

"Labcorp...announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments."

"Labcorp...announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeq technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with early-stage solid tumor cancers."

"Labcorp...announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution in early stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy (ACT). This solution, which is designed for research use but also suitable for clinical applications, can be applied across solid tumors with a scalable and standardized approach to facilitate faster turnaround times while maintaining high analytical performance."